Non Invasive Assessment of Hepatic Fibrosis Regression in Hepatitis C Virus Infected Patients Treated with Sofosbuvir Based Therapy

Abstract

epatitis C virus (HCV) infection in one of worldwide chief causes chronic liver illness. The morbidity and mortality of this global infection are growing. Directly acting antivirals (DAAs) are a new era in treating HCV and considered the key of its management. In hepatitis C virus (HCV)-infected patients, liver fibrosis is a noticeable process and could progress to liver cirrhosis or hepatocellular carcinoma gradually. Liver biopsy is the gold standard for assessing liver fibrosis regression following DAAs treatment, but it is no longer accepted by large number of patients because of invasiveness and higher rate of complications. Therefore, searching for accurate non-invasive parameters to determine the degree of liver fibrosis was essential. Our aim was to evaluate early changes of fibrosis-related parameters in patients with chronic HCV patients by liver stiffness measurement using Shear wave elastography (Siemens-Acuson S2000) and serum parameters as APRI, FIB4 before and after sofosbuvir-based antiviral therapy. This study was conducted on 109 Egyptian patients with chronic hepatitis C who were collected from viral hepatitis treatment unit in Sohag Cardiology and Hepato-Gastroentrology Center and followed up in the period between July 2017 and September 2018.